Amending the basis of your validity challenge in patent litigation is never just a procedural move — it is a strategic play with real commercial consequences. What stands out in AstraZeneca AB v Pharmacor Pty Ltd (No 3) [2026] FCA 565 is a good reminder of how timing, clarity of theory, and disciplined framing of invalidity grounds will directly shape the Court’s willingness to let the patent challenger to expand its case.
The Court allowed the obviousness and PTE‑related amendments because they were grounded, timely once recognised, and strategically coherent. But it refused the late‑breaking best‑method case because it was diffuse, exploratory, and would have derailed a tightly scheduled path to trial. Courts reward structured, well‑reasoned strategy and penalise fishing expeditions dressed up in pleadings.
There’s a broader pattern worth noting. As product lifecycles shorten and regulatory‑linked patent extensions become more valuable, the strategic premium on precision increases. This judgment reinforces that your litigation posture is part of your IP strategy — not an afterthought. A party that cannot articulate its theory of invalidity early and with discipline risks losing the opportunity to run it at all.
Conversely, a party that anticipates pressure points early, aligns its technical and legal teams, and builds a coherent narrative is better positioned to protect or challenge market exclusivity.
Treat amendment decisions as strategic investments. The organisations that win are those that structure their IP strategy to move quickly, argue clearly, and keep the commercial timeline front of mind.
Widening a patent claim is never free. Every limitation you drop to capture more of the market quietly commits you to two things: a disclosure that actually supports the wider claim, and a priority date that can still carry it. Lose sight of either, and the broader claim becomes the weakest point in the portfolio. A recent Full Federal Court decision made the cost concrete — three jump-starter patents were held obvious, several claims lost their earliest priority date and fell for lack of novelty, and the patents failed Australia’s best-method requirement.
The strategic thread running through all three failures was the same: the patentee had broadened its divisional claims by removing specific limitations (a named switch type and a two-sensor arrangement), but the wider claims weren’t disclosed in the original PCT filing, so they slipped to a later priority date — and the Court confirmed that best method is assessed at the filing date of the divisional, not the parent, meaning improvements learned in the years between had to be disclosed and weren’t.
A claim is only as strong as the disclosure and the priority date underneath it, and “broader” and “stronger” are not the same thing. Three checks are worth running across any portfolio built on divisionals: first, does each broadened claim still trace to disclosure in the earliest application, or has it drifted to a priority date that exposes it to intervening prior art; second, where you widened a claim by stripping a limitation, did you disclose the best method known at the divisional filing date for that broader invention; third, are you filing divisionals to protect genuinely distinct inventions, or simply to keep options open in a way that manufactures risk.
Patentees should review portfolios for vulnerability to this ground and consider filing further divisionals to cure any later-discovered best method; international applicants are most exposed, since few jurisdictions outside Australia carry a standalone best-method requirement. Disciplined claim strategy, in the end, is knowing what not to claim — and knowing what you must disclose the moment you decide to claim it.
Read the case here: The NOCO Company v Brown and Watson International Pty Ltd [2026] FCAFC 44
A McKinsey study found that 44% of directors said their boards simply reviewed and approved management’s proposed strategies—and only 10% felt they fully understood the industry dynamics they were governing. For IP-intensive businesses, that gap is expensive. Inventions, brands, data and know-how are often the real engines of return, yet they rarely attract the boardroom scrutiny reserved for revenue and margin. When directors can’t interrogate the IP position—freedom to operate, the durability of a competitive moat, where rivals are quietly filing—they end up approving strategies built on assumptions no one has tested. The result is familiar: defensible-looking plans that carry uninspected risk, and value drivers that go unmanaged precisely because they sit one layer below the numbers everyone watches.
MicKinsey’s suggested remedy translates almost directly to IP. First, build genuine understanding of the landscape before reviewing any plan—treat the portfolio as a value driver, not a compliance line item. Second, force real debate before a strategy is set: ask what a competitor or an acquirer would do with your IP, and whether your protection actually maps to where you create value. Third, wrestle the options to the ground—build, license, acquire or divest—and tie each to capital and talent allocation rather than leaving it to legal housekeeping. Done well, this is what turns IP from a cost centre into a lever for bolder, better-resourced moves.
The discipline isn’t about getting the filings right. It’s about how thoughtful owners decide where to compete.
Worth a read: McKinsey, Tapping the strategic potential of boards.
The most valuable thing a competitor can do to your patent is comply with the law around it. That is the quiet lesson for IP-intensive businesses in the US Supreme Court’s unanimous June 2026 ruling in Hikma v. Amarin (read it here).
Amarin held a method-of-use patent on the cardiovascular indication for its drug Vascepa. Hikma launched a generic under a skinny label that carved out that patented use and kept only the off-patent one. Amarin’s induced infringement claim leaned on the totality of Hikma’s conduct: its label, its leaflet, its website, its investor press releases. The Court was unmoved. Inducement requires affirmative steps to encourage infringement, it held — not statements a physician could read as encouragement, and certainly not routine regulatory compliance, standard equivalence language, or what the drug didn’t say. Omissions, vagueness and “obvious alternative explanations” don’t cross the line.
For brand- side IP Managers, a second medical use patent is a real asset, if you can, figure out and claim all commercially viable indications – because the generic and biosimilar companies will. For generics and biosimilar teams, it confirms that a disciplined carve-out plus genuinely neutral commercial conduct is a defensible launch strategy, though note that Australian courts (Apotex v Sanofi, the pregabalin litigation) look hard at real-world market behaviour and won’t always reach the same result.
The takeaway for any IP-intensive organisation: your competitive position is decided long before litigation, in the choices about what you patent and how you behave commercially around it. Treat IP strategy as a business decision, not a filing exercise — and design your evidence trail, on both sides of the fence, before you need it.
A patent settlement can look perfectly clean on its face and still carry antitrust risk buried in its economics. That is the lesson from an $885 million jury verdict handed down in Boston this month, where Takeda was found liable for effectively paying a generic rival to keep its version of the IBS drug Amitiza off the market. There was no cheque labelled “reverse payment.” Instead, the plaintiffs pointed to the structure of the deal — a 50% royalty that dropped to 15% if a second generic entered, and to zero with a third — and argued it gave Takeda every commercial reason not to launch its own authorised generic. The jury agreed, finding an implicit “no-AG” agreement and a large, unjustified payment under the Actavis rule of reason. It is the first time private plaintiffs have taken a pay-for-delay case all the way to a jury and won, and the damages could treble to roughly $2.5 billion.
How you transfer value matters as much as whether you transfer it. Courts and juries will read the commercial logic of a settlement, not just its wording — and an arrangement engineered to suppress competition will be treated as exactly that, however carefully it is drafted.
Tie any agreed entry date to a genuine, documented assessment of patent strength. Scrutinise royalty schedules, authorised-generic rights and every other lever for incentives that look exclusionary in hindsight. And note the timeline: a 2014 deal was still being unwound in 2026 — settlement decisions have a very long risk period. Strong IP strategy isn’t only about owning strong patents. It’s about structuring the deals around them so the economics tell the same story as the paperwork.
Katten’s analysis of the verdict: https://katten.com/lessons-from-landmark-jury-verdict-in-amitiza-reverse-payment-antitrust-case — and the reporting from FiercePharma: https://www.fiercepharma.com/pharma/takeda-slapped-885m-verdict-pay-delay-antitrust-case
The Unified Patent Court has signalled that its reach extends well beyond its own member states, and IP-intensive businesses should take note. In its 2 June 2026 decision in Fujifilm v Kodak, the UPC Court of Appeal confirmed that Article 34 of the UPC Agreement is not a territorial cap—where a defendant is domiciled in UPC territory, the Court can hear infringement claims tied to national designations of European patents in non-UPC countries, including the UK. The strategic point is that domicile, not the location of the alleged acts, is now the anchor. For patent owners, that opens a single forum to pursue cross-border relief that once required parallel suits in multiple jurisdictions.
For potential defendants, it means a German (or other UPC-state) corporate footprint can pull your UK and other foreign exposure into one court—worth factoring into where you incorporate, manufacture, and hold title.
But accepting jurisdiction is one thing; exercising it is another, and that distinction is where the commercial discipline lies. The Court built in safeguards through comity: it can grant relief on foreign designations subject to a condition that the patent isn’t later found invalid by the competent national court, giving defendants a clear incentive to move fast in national revocation forums if they want to resist a long-arm injunction. And clearing the jurisdictional hurdle guarantees nothing on the merits—Fujifilm’s UK claim ultimately failed because, under UK law, supplying goods abroad to a party that later imports them isn’t enough for joint tortfeasorship.
The takeaway for IP strategy: map your domicile and supply-chain structure against this expanded reach, decide early whether to maintain or withdraw extra-territorial claims, and remember that winning jurisdiction is the start of the contest, not the end of it.
Bristows’ full Rapid Reaction analysis is worth reading in full: https://inquisitiveminds.bristows.com/post/102n0w7/rapid-reaction-upc-court-of-appeal-clarifies-the-approach-to-long-arm-claims-fu
A confidential drawing sent to you for a single, narrow purpose does not become yours to repurpose — and treating it as though it does can unravel an entire IP position. That is the strategic core of the Full Federal Court’s decision in Comino v Watson Webb Pty Ltd [2026] FCAFC 66. A distributor received a manufacturer’s confidential engineering drawing to “sign off” before production, stripped the markings, and registered the design in his own name. The Court confirmed that the obligation of confidence bound him regardless of his own contribution to the design, and even though key witnesses were never called.
For IP-intensive businesses the lesson is uncomfortable but clear: inbound IP is a constraint, not a windfall. Every drawing, sample and spec that arrives under an obligation of confidence narrows what you can later claim as your own — and disregard of that line is what invited additional damages here.
The appeal is just as instructive for what it corrected. The Court set aside a constructive trust that had handed the manufacturer the entire design, because the distributor was a genuine co-designer — remedies track contribution, not punishment. More striking is the threats ruling: a letter demanding undertakings and reserving the right to sue is prima facie an unjustified threat unless you can prove infringement, and quietly dropping the claim later will not save you.
Three takeaways for leaders and in-house counsel:
- fix ownership in writing before development starts;
- treat others’ confidential material as off-limits, not raw material; and
- never send an enforcement letter you are not prepared to back in court.
Disciplined IP strategy is less about owning the most rights than knowing precisely how to use them.
A registered design buys you a finite head start, not a permanent moat. When it lapses, competitors are free — and, the law says, encouraged — to copy. The Federal Court’s decision in Bodum AG v H.A.G Import Corpn (Australia) Pty Ltd [2026] FCA 238 provides a good illustration.
Bodum’s double-walled glasses enjoyed a decade of design protection; once it expired, Maxwell & Williams openly copied the exact shape, admitted as much, and sold a near-identical product more cheaply. Bodum tried to stretch its protection through misleading-conduct and passing-off claims, and lost. The strategic reason matters more than the result: Bodum had never built a secondary reputation in the shape itself. Consumers recognised the BODUM word mark and logo — not the bare silhouette. Ironically, the strength of the brand undercut the claim. Buyers identified the product by the name on it, so a glass without that name read as “not Bodum,” not “a cheaper Bodum.” Deliberate copying, the Court confirmed, is not the same as an intention to deceive — and a strong rival brand plus clear labelling will usually defeat the claim.
For IP-intensive businesses, the lesson is about sequencing and evidence, not litigation. Treat every finite right — a design, a patent — as a window to build something durable, not as the protection itself. If a shape is commercially important, work deliberately to make it distinctive of you: promote the shape as a brand signifier, consider a shape trade mark (renewable indefinitely), and keep the proof — distribution figures, readership, campaigns that feature the shape without the logo.
Bodum’s marketing was extensive but unfocused: the glasses were two of more than twenty-five double-walled designs, rarely shown unbranded, and the evidence of standalone shape recognition simply wasn’t there. The disciplined move is to convert a temporary monopoly into lasting brand equity before the clock runs out — and to document that recognition as you go, so the get-up can carry its own weight when the registration can’t.
Full decision here: https://www.austlii.edu.au/cgi-bin/viewdoc/au/cases/cth/FCA/2026/238.html
Strip the case names away and one pattern runs through this month’s posts: the decisive moment in an IP matter almost never happens in the courtroom. It happens years earlier — in the words drafted into a claim, the honesty of a brand at first use, the rigour of a specification, the provenance of training data, the structure of a portfolio. May delivered a run of decisions and developments that all reward the same discipline: getting the groundwork right before anyone is watching. For IP strategists, the signal is consistent. Enforcement tests work done long ago. Plan accordingly.
Disputes & Litigation
Three decisions this month make the same uncomfortable point — your earlier conduct becomes the evidence you later have to live with. The patent claim-drafting decision over the Bayer process confirmed that overbroad language fails post-Raising the Bar support and sufficiency tests, and that claim scope must map to what the specification actually enables. The High Court’s ruling on the honest concurrent use defence fixed honesty at first use of the mark, making brand clearance a decision point that sets your position for the mark’s life. And a quieter procedural decision confirmed that fresh acts of infringement can support fresh proceedings against a familiar opponent — a reminder that procedural clarity is leverage, not housekeeping.
Patents
The patent posts reinforce that theme from the asset side: the insufficiency and best-method failure in Orikan shows how fast a patent loses strategic value when the disclosure can’t carry the weight placed on it. Priority claims, knowledge capture and specification drafting are strategic processes — treat them as administrative tasks and the gap shows up in court.
Trade Marks & Brand Governance
Beyond first-use honesty, the brand dispute resulting in injunctions and a forced name change shows the upside of doing the groundwork: clean chains of title and procedural discipline let the successful party secure broad remedies, including trade mark cancellation and indemnity costs. Well-structured IP governance converts directly into commercial leverage.
Copyright, AI & the Price of Data
Two posts track the same fast-moving front — the value of content as AI training input. The scrutiny of Anthropic’s US$1.5B settlement reframes training-data valuation as a balance-sheet issue, making provenance, licensing posture and reserve planning board-level concerns. The EU’s move to put a licensing framework for AI training on the statute book then shifts the contest from courtroom to legislation, in the jurisdiction whose rules tend to become everyone’s — so decide whether you lead as a licensor or a licensee, document provenance, and engage the consultation while the rules are still being written.
Deals, Budget & Strategy
The strategic posts pull the month together. The Federal Budget’s R&D, ESS and CGT changes reshape how IP-intensive firms fund innovation and time their investments, forcing IP strategy to integrate with capital allocation and organisational design. And the argument that AI efficiency is not a durable advantage lands the same point from the offensive side: lasting advantage comes from combining proprietary data, patents and protected workflows into AI-native offerings competitors can’t easily replicate.
What to Watch
The through-line is clear enough to act on. Courts and regulators are pushing the decisive moment upstream — into drafting, clearance, provenance and portfolio structure — and rewarding the parties who treated those steps as strategy rather than process. Two fronts deserve attention in the months ahead. First, the post-RTB enforcement standard is tightening; audit live claim sets and specifications against the construction arguments an opponent would actually run, before a dispute forces the question. Second, the AI training-data market is being priced and legislated in real time; the organisations that can prove provenance and have decided their licensor-versus-licensee posture will negotiate from strength while others are still reacting.
The decisions of the next quarter will keep testing work done long before them. The IP Strategies that win have already been build, well ahead of when they are truly tested.
A decade-long battle over an anti-scaling method for the Bayer process has just delivered a sharp reminder that patent claims are commercial instruments, not afterthoughts. In Nalco Company v Cytec Industries Inc [2026] FCAFC 72, the Full Federal Court upheld findings that Nalco’s original claims failed the post-Raising the Bar support and sufficiency thresholds — because the language admitted within its scope a composition the specification never taught how to make.
The phrase “at least one small molecule” looked innocuous on the page. In practice, it stretched the monopoly beyond what the technical contribution could justify, and no amount of expert evidence about statistical improbability could rescue it. The Court was clear: low probability of an embodiment is not the same as exclusion, and the words a patentee chooses will be given work to do.
The strategic lesson runs deeper than drafting hygiene. Nalco eventually secured its amendments on appeal — but only after years of litigation, six amendment rounds, and a Full Court willing to exercise the s 105(1A) discretion afresh. That outcome turned on disciplined conduct: timely amendments, full and frank disclosure, and a credible narrative that each iteration responded to issues as they crystallised rather than to risks long known and ignored.
For IP-intensive businesses, three patterns are worth internalising.
First, the post-RTB regime rewards claim scope that maps tightly to what the specification actually enables — aspirational breadth is now a liability, not an option.
Second, opposition and appeal strategy should include pre-built fallback claim sets, stress-tested against the construction arguments your opponent is most likely to run.
Third, the discretion to amend remains genuinely available where the patentee behaves transparently — but culpable delay, tactical obscurity, or knowingly maintaining overbroad claims will close that door.
The patent bargain is being enforced more strictly than it once was; the businesses that treat claim drafting as a strategic exercise — not a downstream task — will be the ones still holding their monopolies when challenges come.
Read the full judgment here.
You must be logged in to post a comment.